Literature DB >> 31873972

In Reply.

Kathryn E Flynn1, David J Vanness2, Judith M Myers1, Anita D'Souza1, Charles A Schiffer3, James E Thompson4, Ehab Atallah1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31873972      PMCID： PMC7160403          DOI： 10.1634/theoncologist.2019-0890

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  4 in total

1.  Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Authors:  Kathryn E Flynn; Michael J Mauro; Gemlyn George; Alexander Hinman; Arielle Baim; Vamsi Kota; Richard A Larson; Jeffrey H Lipton; James E Thompson; Martha Wadleigh; Ehab Atallah
Journal:  Leuk Res       Date:  2019-03-28       Impact factor: 3.156

2.  Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Authors:  Kathryn E Flynn; Judith M Myers; Anita D'Souza; Charles A Schiffer; James E Thompson; Ehab Atallah
Journal:  Oncologist       Date:  2019-04-03

3.  Understanding choice: why physicians should learn prospect theory.

Authors:  Amol A Verma; Fahad Razak; Allan S Detsky
Journal:  JAMA       Date:  2014-02-12       Impact factor: 56.272

4.  Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Authors:  Ehab Atallah; Charles A Schiffer; Kevin P Weinfurt; Mei-Jie Zhang; Jerald P Radich; Vivian G Oehler; Javier Pinilla-Ibarz; Michael W N Deininger; Li Lin; Richard A Larson; Michael J Mauro; Joseph O Moore; Ellen K Ritchie; Neil P Shah; Richard T Silver; Martha Wadleigh; Jorge Cortes; James Thompson; Jessica Guhl; Mary M Horowitz; Kathryn E Flynn
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.